Loading
Immunotherapy works in tumours that immune cells can enter and ignores those that shut them out. Systematically test ways to open up the shut-out tumours, measured with spatial maps.
Most pancreatic, prostate, colorectal (microsatellite-stable), ovarian and glioma tumours are immune-excluded or immune-desert. Candidate strategies include stromal modulation (FAP, TGF-beta, CXCR4 antagonists), innate agonists (STING, TLR), oncolytic viruses, radiotherapy priming, and myeloid reprogramming (CD47, CSF1R). Each has been tested piecemeal. The proposal is a coordinated programme with standardised spatial immune profiling before and after each intervention in window-of-opportunity trials, a shared classification of exclusion mechanisms, and adaptive combination trials that match the mechanism of exclusion to the reprogramming strategy.
One of the most cited reviews Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD47 in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Two bottleneck pages and 32 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review, Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade, Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer, STING & innate immune agonists.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares STING & innate immune agonists, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Single-cell & spatial profiling, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, FAP, Single-cell & spatial profiling, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Pancreatic ductal adenocarcinoma.